1. Home
  2. IMRN vs GOVX Comparison

IMRN vs GOVX Comparison

Compare IMRN & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • GOVX
  • Stock Information
  • Founded
  • IMRN 1994
  • GOVX 2001
  • Country
  • IMRN Australia
  • GOVX United States
  • Employees
  • IMRN N/A
  • GOVX N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • GOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMRN Health Care
  • GOVX Health Care
  • Exchange
  • IMRN Nasdaq
  • GOVX Nasdaq
  • Market Cap
  • IMRN 14.4M
  • GOVX 16.8M
  • IPO Year
  • IMRN N/A
  • GOVX N/A
  • Fundamental
  • Price
  • IMRN $1.58
  • GOVX $0.40
  • Analyst Decision
  • IMRN
  • GOVX Strong Buy
  • Analyst Count
  • IMRN 0
  • GOVX 2
  • Target Price
  • IMRN N/A
  • GOVX $8.50
  • AVG Volume (30 Days)
  • IMRN 384.6K
  • GOVX 569.4K
  • Earning Date
  • IMRN 08-29-2025
  • GOVX 11-13-2025
  • Dividend Yield
  • IMRN N/A
  • GOVX N/A
  • EPS Growth
  • IMRN N/A
  • GOVX N/A
  • EPS
  • IMRN N/A
  • GOVX N/A
  • Revenue
  • IMRN $4,777,422.00
  • GOVX $3,353,560.00
  • Revenue This Year
  • IMRN N/A
  • GOVX N/A
  • Revenue Next Year
  • IMRN N/A
  • GOVX N/A
  • P/E Ratio
  • IMRN N/A
  • GOVX N/A
  • Revenue Growth
  • IMRN 48.63
  • GOVX 8.52
  • 52 Week Low
  • IMRN $1.42
  • GOVX $0.40
  • 52 Week High
  • IMRN $2.48
  • GOVX $3.15
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 33.02
  • GOVX 27.77
  • Support Level
  • IMRN $1.54
  • GOVX $0.46
  • Resistance Level
  • IMRN $1.62
  • GOVX $0.52
  • Average True Range (ATR)
  • IMRN 0.13
  • GOVX 0.04
  • MACD
  • IMRN -0.03
  • GOVX -0.01
  • Stochastic Oscillator
  • IMRN 18.84
  • GOVX 7.88

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: